Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06131216
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-14
First Post:
2023-11-08
Brief Title:
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
Sponsor:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Organization:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Study Overview
Official Title:
Phase I Clinical Study on the Safety Tolerability Pharmacokinetics and Efficacy of SHR-2022 Injection Alone or in Combination With Other Anti-tumor Treatments in Patients With Advanced Malignant Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None